MUC1 oncoprotein is a druggable target in human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3056-3065

  Joshi, Maya Datt ^a   Ahmad, Rehan ^a   Yin, Li ^a   Raina, Deepak ^b   Rajabi, Hasan ^a   Bubley, Glenn ^a   Kharbanda, Surender ^b   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Genus Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CP 1; GO 201; MUCIN 1; PEPTIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER SURVIVAL; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; DISEASE PROGRESSION; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; MUCIN-1; OXIDATION-REDUCTION; PEPTIDES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70450268120     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0646     Document Type: Article

References (50)

1. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-232 (Pubitemid 15184701)
2. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992;267:6171-6177
3. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003;22:6107-6110 (Pubitemid 37175889)
4. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005;65:10413-10422
5. Li Y, Ren J, Yu W-H, et al. The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem 2001;276:35239-35242
6. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007;27:992-1004. (Pubitemid 47488189)
7. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J Biol Chem 1997;272:12492-12494 (Pubitemid 27203339)
8. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005;7:167-178 (Pubitemid 40248342)
9. Ahmad R, Raina D, Trivedi V, et al. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signaling. Nat Cell Biol 2007;9:1419-1427 (Pubitemid 350201755)
10. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res 2009;69:7013-7021
11. Leng Y, Cao C, Ren J, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007;282:19321-19330 (Pubitemid 47100108)
12. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell 2004;5:163-175 (Pubitemid 38283802)
13. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006;25:20-31. (Pubitemid 43050000)
14. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006;4:873-883 (Pubitemid 44877017)
15. Yin L, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003;278:35458-35464 (Pubitemid 37102316)
16. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004;279:45721-45727 (Pubitemid 39491562)
17. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1α activation in a survival response to hypoxia. J Biol Chem 2007;282:257-266 (Pubitemid 47076647)
18. Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol 2009;34:1691-1699
19. Raina D, Ahmad R, Joshi M, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009;69:5133-5141
20. Cozzi PJ, Wang J, Delprado W, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005;22:565-573 (Pubitemid 43234641)
21. Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 1999;3:163-168 (Pubitemid 29511032)
22. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-816
23. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261
24. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
25. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-490
26. Mohler JL, Gregory CW, Ford OH, III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448
27. Kang Z, Jänne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-2648
28. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478
29. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013 (Pubitemid 34160279)
30. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39 (Pubitemid 38524696)
31. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-790
32. Jones JO, Bolton EC, Huang Y, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A 2009;106:7233-7238
33. Xu K, Shimelis H, Linn DE, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009;15:270-282
34. Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and β-catenin in castrate-resistant prostate cancer. Cancer Res 2008;68:9918-9927
35. Chen Y, Sawyers C, Scher H. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-448
36. Gasparian A, Yao Y, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141-151
37. McGahon AJ, Martin SJ, Bissonnette RP, et al. The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol 1995;46:153-185
38. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-6614
39. Navone N, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-2500 (Pubitemid 28133173)
40. Cha T, Qiu L, Chen C, Wen Y, Hung M. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005;65:2257-2295
41. Fischer PM. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006. Med Res Rev 2007;27:755-795
42. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007; 47:143-183 (Pubitemid 46272127)
43. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99-163. (Pubitemid 46209992)
44. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20:1-15.
45. Andrén O, Fall K, Andersson SO, et al. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97:730-734 (Pubitemid 47396290)
46. Rabiau N, Dechelotte P, Guy L, et al. Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo 2009;23:203-207
47. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995;55:4000-4003
48. Bitler B, Menzl I, Huerta C, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009;15:100-109
49. Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-4713 (Pubitemid 30701475)
50. Yang F, Li X, Sharma M, et al. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-11344